GOMEKLI (Mirdametinib) Patent Expiration, LOE Window & CMS Spending

GOMEKLI (Mirdametinib) by Springworks Therapeutics: FDA Orange Book core substance LOE 2044-03-15 (last listed 2044-10-10), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $34,650 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSpringworks Therapeutics
FDA Application & PathwayN219379 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2044-03-15
Last Listed Patent or Exclusivity Date2044-10-10
Orange Book Patents (*PED Extensions)53 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($34,650 intro WAC)